Taro Pharmaceutical Industries Ltd. TARO

Full chart Compare
Set alert

Price alert · TARO

All alert types
42.98 0.00 (+0.00%)

Jun 21, 2024, 3:59 PM EDT

42.94 Day range 42.98

52-week range unavailable

Market cap
1.62B
Revenue (ttm)
629.18M
Profit margin
8.56%
Shares out
37.58M
Forward P/E
9.79
Volume
147.06K
Open
42.97
Previous close
42.98
Day's range
42.94 – 42.98
Beta
0.56
Analysts
Hold
Price target
43.00 (+0.1%)
Earnings date
Jul 24, 2024

 

No chart data for this range yet.

Key statistics

Enterprise value
735.67M
PEG ratio
0.00
Price / sales
2.57
Price / book
0.90
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
12.50%
Free cash flow
21.04M
Total cash
879.35M
Total debt
0
Return on equity
3.06%
Short % of float
0.91%
50-day average
42.53
200-day average
40.34

Financials — quick view

All financials
TARO Revenue — quarterly 164.94M
2021-Q1 20202021-Q2 20202021-Q3 20202021-Q4 20212022-Q1 20212022-Q2 20212022-Q3 20212022-Q4 20222023-Q1 20222023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 2024
TARO Net income — quarterly 15.08M
2021-Q1 20202021-Q2 20202021-Q3 20202021-Q4 20212022-Q1 20212022-Q2 20212022-Q3 20212022-Q4 20222023-Q1 20222023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 2024
TARO EPS — quarterly 0.40
2021-Q1 20202021-Q2 20202021-Q3 20202021-Q4 20212022-Q1 20212022-Q2 20212022-Q3 20212022-Q4 20222023-Q1 20222023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 2024

Earnings

TARO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jul 24, 2024Jun 1, 20240.00———
May 20, 2024Mar 1, 20240.00———
Jan 25, 2024Dec 1, 20230.30———
Oct 26, 2023Sep 1, 20230.18———
Jul 26, 2023Jun 1, 20230.31———
May 23, 2023Mar 1, 20230.23———

Upgrades / downgrades

TARO analyst upgrades and downgrades
DateFirmActionFromTo
Jan 24, 2023HC Wainwright & Co.main—Buy
Aug 14, 2022HC Wainwright & Co.main—Buy
Jan 30, 2022HC Wainwright & Co.main—Buy
Jan 17, 2022HC Wainwright & Co.main—Buy
Jul 27, 2021HC Wainwright & Co.main—Buy
Jun 1, 2021HC Wainwright & Co.main—Buy

About Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Country
Israel
Website
taro.com

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on TARO — it syncs with the Stock Master app.

Insider holders

TARO insider holders
InsiderRelationLatest transactionDateShares held
FRANKLIN RESOURCES INCBeneficial Owner of more than 10% of a Class of SecuritySaleOct 31, 20100
SUN PHARMACEUTICAL INDUSTRIES, LTD.Affiliated PersonPurchaseNov 3, 20100

Institution ownership

TARO institution ownership
Holder% heldSharesValueReported
Krensavage Asset Management, LLC1.71%643,08024.39MJun 29, 2023
Renaissance Technologies, LLC1.58%594,90022.56MJun 29, 2023
Blackrock Inc.1.55%581,83822.07MJun 29, 2023
Dimensional Fund Advisors LP1.47%552,16220.94MJun 29, 2023
Brandes Investment Partners L.P.1.26%472,89917.94MJun 29, 2023
Eversept Partners, LP0.67%250,2869.49MJun 29, 2023

Fund ownership

TARO fund ownership
Holder% heldSharesValueReported
Invesco ETF Tr-Invesco Dynamic Pharmaceuticals ETF0.71%266,80110.57MAug 30, 2023
Columbia Fds Ser Tr I-Columbia Small Cap Value Fd I0.51%191,4537.00MJul 30, 2023
iShares Russell 2000 ETF0.49%184,4977.31MAug 30, 2023
Brandes International Small Cap Equity Fund0.22%83,2503.16MJun 29, 2023
DFA U.S. Core Equity 2 Portfolio0.22%83,2533.04MJul 30, 2023
Fidelity Small Cap Index Fund0.20%73,5072.69MJul 30, 2023